Innoviva (INVA) Cash & Equivalents (2009 - 2026)

Innoviva (INVA) has 18 years of Cash & Equivalents data on file, last reported at $603.1 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents rose 89.0% year-over-year to $603.1 million; the trailing twelve-month figure through Mar 2026 stood at $603.1 million (up 89.0% YoY), and the FY2025 full-year result was $550.9 million, up 80.66% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $603.1 million, up from $550.9 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $603.1 million in Q1 2026 and bottomed at $144.0 million in Q1 2023.
• The 5-year median for Cash & Equivalents is $283.6 million (2022), against an average of $299.5 million.
• The widest annual swing landed in 2022, when Cash & Equivalents jumped 555.45%; it then plunged 40.16% in 2023.
• A 5-year view of Cash & Equivalents shows it stood at $291.0 million in 2022, then plunged by 33.51% to $193.5 million in 2023, then jumped by 57.59% to $305.0 million in 2024, then jumped by 80.66% to $550.9 million in 2025, then advanced by 9.46% to $603.1 million in 2026.
• The last three Cash & Equivalents figures came in at $603.1 million (Q1 2026), $550.9 million (Q4 2025), and $476.5 million (Q3 2025), per Business Quant data.

Peer Comparison